<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076019</url>
  </required_header>
  <id_info>
    <org_study_id>STARC210421_2</org_study_id>
    <nct_id>NCT05076019</nct_id>
  </id_info>
  <brief_title>Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement</brief_title>
  <acronym>STARC</acronym>
  <official_title>Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense Patient Data Explorative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GCP-unit at Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins have rapid and significant actions that have potentially important (but not yet&#xD;
      proven) implications for postoperative atrial fibrillation and cardiac protection in patients&#xD;
      undergoing cardiac surgery.&#xD;
&#xD;
      The focus of this study is, therefore, on patients having surgical aortic valve replacement&#xD;
      (with aortotomy) and the development of postoperative atrial fibrillation (POAF). Our aims&#xD;
      are: to examine the ability of a clinically durable Atorvastatin prophylactic regime to&#xD;
      prevent the development of POAF and other postoperative complications in these patients.&#xD;
&#xD;
      Patients will be randomized to Atorvastatin 80mg or placebo 7 to 14 days preoperative until&#xD;
      30 days postoperative - a total of 37 to 44 days of treatment.&#xD;
&#xD;
      The medication will be double blinded.&#xD;
&#xD;
      The randomized studie will address 3 separate hypotheses in patients undergoing open heart&#xD;
      operation with solitary aortic valve replacement with a bioprosthetic valve that&#xD;
&#xD;
        1. 7 to 14 days preoperative and until 30 days postoperative treatment with Atorvastatin 80&#xD;
           mg daily reduces the incidence of POAF in statin-naïve patients.&#xD;
&#xD;
        2. 7 to 14 days preoperative and until 30 days postoperative treatment with Atorvastatin 80&#xD;
           mg daily reduce early (&lt;30 days) and intermediate (&lt;1 year) mortality, MI, stroke and&#xD;
           rehospitalisation in statin-naïve patients.&#xD;
&#xD;
        3. Atorvastatin 80 mg daily reduces the myocardial injury and inflammatory response and&#xD;
           improves cardiac and renal function in statin-naïve patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial Participants:&#xD;
&#xD;
      Enrolment for the study is planned to start February 2022 and continue until 266 patients&#xD;
      have been enrolled.&#xD;
&#xD;
      Course of action:&#xD;
&#xD;
      Patients undergoing elective surgical aortic valve replacement with bioprosthesis at the&#xD;
      Department of Cardiac Surgery at Odense University Hospital will be offered participation in&#xD;
      the study.&#xD;
&#xD;
      Potentially eligible patients will be screened according to inclusion/exclusion criteria at&#xD;
      the time after eligibility of surgery. This is assessed at a multidisciplinary team (MDT)&#xD;
      conference (with attendance of cardiologist, cardiac surgeons and anaesthesiologist) based on&#xD;
      clinical evaluation, echocardiographic ultrasound, coronary angiography and lung function&#xD;
      test.&#xD;
&#xD;
      Patients eligible to participate in the study will be presented with the information of the&#xD;
      study at the time of their out-patient appointment, according to normal routine at Odense&#xD;
      University Hospital. At this appointment the patient receives a physical examination and&#xD;
      journal record is obtained by a cardiac surgeon (approximately 7 to 14 days prior to planned&#xD;
      surgery).&#xD;
&#xD;
      The study-information will be given by one of the participating doctors, while the patient&#xD;
      has been informed of the possibility of bringing an assessor of their choice. The information&#xD;
      will be delivered in a quiet room blocked to other appointments in the Department of&#xD;
      Cardiothoracic Surgery.&#xD;
&#xD;
      During this meeting the patient will be informed of the purpose of this study and the written&#xD;
      patient information will be submitted in detail. Patients will be given as much time as&#xD;
      wanted after the oral information has been delivered to decide if they wish to participate in&#xD;
      the study. Patients will be offered the possibility to call one of the doctors taking part in&#xD;
      this study during this time, in case of additional questions. Subjects can leave the study at&#xD;
      any time for any reason if they wish to do so, without any consequences.&#xD;
&#xD;
      Signed informed consent will be provided prior to any research procedures. A subject is&#xD;
      registered when signed informed consent has been provided and assigned a subject&#xD;
      identification code by the computer-generated code. A subject is randomized when a treatment&#xD;
      and a randomisation number has been provided. A subject is considered enrolled in the study&#xD;
      once the subject is randomized.&#xD;
&#xD;
      Patient data from EHR will be conducted according to study endpoints after signed informed&#xD;
      consent is provided. Signed consent gives sponsor and sponsors representatives&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Allocation to a numbered treatment pack (Atorvastatin or placebo - blinded) Randomization&#xD;
      scheme will be set-up by OPEN data manager with control for beta-blockers and age, and then&#xD;
      randomization per se will be executed with the use of REDCap.&#xD;
&#xD;
      The following will be recorded at the day of randomization:&#xD;
&#xD;
        -  Conduct information for baseline characteristics&#xD;
&#xD;
        -  Transthoracic Echocardiography measurements&#xD;
&#xD;
      Collect baseline blood sample:&#xD;
&#xD;
      • Troponin, CK-MB, Creatinine, CRP&#xD;
&#xD;
      Commence study medication/treatment&#xD;
&#xD;
      Perioperative interventions and outcomes from the day of surgery to the day of discharge:&#xD;
&#xD;
        -  Duration of aortic cross clamp (ACC), extracorporeal circulation (ECC), ventilatory&#xD;
           support, intensive care unit stay period, hospital stay period&#xD;
&#xD;
        -  Continue study medication&#xD;
&#xD;
        -  Blood samples:&#xD;
&#xD;
             -  Preoperative: Troponin, CK-MB, Creatinine, CRP, Plasma-Atorvastatin&#xD;
&#xD;
             -  Serial troponin and CK-MB levels: (6, 24, 48, and 120 hours after surgery).&#xD;
&#xD;
             -  Creatinine levels: 48 and 120 hours after surgery.&#xD;
&#xD;
             -  CRP levels: 48 and 120 hours after surgery&#xD;
&#xD;
        -  Monitor ECG by continuous Holter monitoring to commence as soon as possible after&#xD;
           surgery and continue up to post-operative day 5 evening&#xD;
&#xD;
        -  Transthoracic Echocardiography on post-operative day 5&#xD;
&#xD;
        -  Record fluid intake and output during the first 48 hours following surgery based on IV&#xD;
           fluids administration, blood transfusion (if applicable), oral/nasogastric intake, and&#xD;
           urine plus surgical drain output&#xD;
&#xD;
        -  Record intraoperative defibrillation, removal of external pacemaker, new PPM/ICD,&#xD;
           vasopressors, blood transfusion, surgical re-exploration, renal replacement therapy,&#xD;
           beta-blockers, ACEi/ARB, Amiodarone, Digoxin, Diuretics, Calcium channel blockers,&#xD;
           Potassium supplements, NSAIDs or steroids, non-study statin, use of nephrotoxic&#xD;
           antibiotics, contrast agents or potassium sparing diuretics (Yes/No)&#xD;
&#xD;
      Assessment at/after discharge from hospital:&#xD;
&#xD;
        -  Continue study medications for 30 days after the surgery&#xD;
&#xD;
        -  Phone call on the 30th postoperative day to evaluate symptoms of discomfort compatible&#xD;
           with atrial fibrillation&#xD;
&#xD;
        -  At the end of the study, all excess study medication can be returned at the local&#xD;
           drugstore for safe disposal&#xD;
&#xD;
        -  Patient data from EHR will be conducted according to study endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">February 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention: Atorvastatin, n = 133 Dose: 80 mg/daily P.O. Length of preoperative statin exposure: 7 to 14 days prior to surgery Length of postoperative exposure: 30 days Control group: Placebo, n = 133&#xD;
Study parameters Incidence, placebo group: 36% Incidence, Atorvastatin group: 20% Alpha: 0.05 Beta: 0.2 Power: 0.8 Enrolment ratio: 1:1&#xD;
Sample size Placebo: 133 Atorvastatin: 133</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A unique identifier (code) will be generated for all patients to allow for data management.&#xD;
The list of patients enrolled in the study is available to the data and safety monitoring board. Patients, physicians, nurses, and other data collectors are kept blinded to the allocation during the study.&#xD;
The study medication is allocated in identical non-transparent containers. The placebo resembles the study drug for taste, smell, color, and shape.&#xD;
Hospital pharmacy will be responsible for packaging the medicine, blinding and create sealed code envelopes in case of urgent need for unblinding.&#xD;
The unblinding of study 2 is planned to take place when the last patients has been followed for at least 30 days and early data analysis have been statistically treated while data is still blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with POAF - In-hospital</measure>
    <time_frame>In-hospital up to 10 days</time_frame>
    <description>In-hospital POAF assessed by Holter monitoring.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with POAF - Early</measure>
    <time_frame>Early (≤30 days) incidence of POAF</time_frame>
    <description>Early assessed by anamnesis and electronic health record (EHR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with POAF - Intermediate</measure>
    <time_frame>Intermediate (1 year) incidence of POAF</time_frame>
    <description>Intermediate POAF assessed by anamnesis and EHR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of All-cause mortality - In-hospital</measure>
    <time_frame>In hospital up to 10 days</time_frame>
    <description>To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes.&#xD;
Number of deaths in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All-cause mortality - Early</measure>
    <time_frame>Early (≤30 days)</time_frame>
    <description>To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes.&#xD;
Number of deaths in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All-cause mortality - intermediate</measure>
    <time_frame>intermediate (1 year)</time_frame>
    <description>To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes.&#xD;
Number of deaths in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury - Tn</measure>
    <time_frame>After surgery until discharge up to 10 days.</time_frame>
    <description>Injury assessed by serial Troponin measurements. Unit:ng/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury - CKMB</measure>
    <time_frame>After surgery until discharge up to 10 days.</time_frame>
    <description>Injury assessed by serial CKMB measurements. Unit: μg/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke - Early</measure>
    <time_frame>Early (≤30 days)</time_frame>
    <description>Number of patients with stroke in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke - Intermediate</measure>
    <time_frame>Intermediate (1 year)</time_frame>
    <description>Number of patients with stroke in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trans ischemic attack - Early</measure>
    <time_frame>Early (≤30 days)</time_frame>
    <description>Number of patients with trans ischemic attack in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trans ischemic attack - Intermediate</measure>
    <time_frame>Intermediate (1 year)</time_frame>
    <description>Number of patients with trans ischemic attack in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction - Early</measure>
    <time_frame>Early (≤30 days)</time_frame>
    <description>Number of patients with Myocardial infarction in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction - Intermediate</measure>
    <time_frame>Intermediate (1 year)</time_frame>
    <description>Number of patients with Myocardial infarction in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent pacemaker - Early</measure>
    <time_frame>Early (≤30 days)</time_frame>
    <description>Number of patients with Permanent pacemaker in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent pacemaker - Intermediate</measure>
    <time_frame>Intermediate (1 year)</time_frame>
    <description>Number of patients with Permanent pacemaker in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICD implantation - Early</measure>
    <time_frame>Early (≤30 days)</time_frame>
    <description>Number of patients with ICD implantation in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICD implantation - Intermediate</measure>
    <time_frame>Intermediate (1 year)</time_frame>
    <description>Number of patients with ICD implantation in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury - Early</measure>
    <time_frame>Early (≤30 days)</time_frame>
    <description>Number of patients with Acute kidney injury in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury - Intermediate</measure>
    <time_frame>Intermediate (1 year)</time_frame>
    <description>Number of patients with Acute kidney injury in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).</time_frame>
    <description>Describe echocardiography assessed differences in pre and postoperative measurements of LVEF(left ventricular ejection fraction) between groups. Unit: %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strain</measure>
    <time_frame>Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).</time_frame>
    <description>Describe echocardiography assessed differences in pre and postoperative measurements of Strain between groups.Unit: %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak gradient</measure>
    <time_frame>Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).</time_frame>
    <description>Describe echocardiography assessed differences in pre and postoperative measurements of peak gradient between groups. Unit: mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean gradient</measure>
    <time_frame>Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).</time_frame>
    <description>Describe echocardiography assessed differences in pre and postoperative measurements of mean gradient between groups. Unit: mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAPSE</measure>
    <time_frame>Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).</time_frame>
    <description>Describe echocardiography assessed differences in pre and postoperative measurements of TAPSE (tricuspid annular plane systolic excursion) between groups. Unit: mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay on ICU</measure>
    <time_frame>Day of surgery to the day of discharge from ICU. Up to 52 weeks.</time_frame>
    <description>Length of stay on ICU after surgery. Unit: Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>Day of surgery to the day of discharge. Up to 52 weeks.</time_frame>
    <description>Length of stay in hospital after surgery. Unit: Days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Postoperative Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80mg</intervention_name>
    <description>Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative</description>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing elective solitary SAVR with bioprosthesis&#xD;
&#xD;
          2. Patients who are in sinus rhythm and not taking any anti-arrhythmic medication, other&#xD;
             than beta-adrenergic blocking agents, at the time of surgery&#xD;
&#xD;
          3. No prior use of HMG-CoA reductase inhibitors the last 3 months and at least 7 days&#xD;
             prior to the time of surgery&#xD;
&#xD;
          4. Age &gt;60 years&#xD;
&#xD;
          5. Willingness and provision of informed consent to be randomized&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of atrial fibrillation&#xD;
&#xD;
          2. Prior history of cardiac surgery&#xD;
&#xD;
          3. Known adverse reaction to HMG-CoA reductase inhibitors&#xD;
&#xD;
          4. Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit)&#xD;
&#xD;
          5. Creatinine &gt;200 µmol/L&#xD;
&#xD;
          6. Known intolerance to statins or history of muscle toxicity with statins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lytfi Krasniqi, MD</last_name>
    <phone>42772085</phone>
    <email>Lytfi.krasniqi@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Peter Riber, MD</last_name>
    <phone>21450354</phone>
    <email>lars.riber@rsyd.dk</email>
  </overall_contact_backup>
  <reference>
    <citation>LaPar DJ, Crosby IK, Rich JB, Fonner E Jr, Kron IL, Ailawadi G, Speir AM; Investigators for Virginia Cardiac Surgery Quality Initiative. A contemporary cost analysis of postoperative morbidity after coronary artery bypass grafting with and without concomitant aortic valve replacement to improve patient quality and cost-effective care. Ann Thorac Surg. 2013 Nov;96(5):1621-7. doi: 10.1016/j.athoracsur.2013.05.050. Epub 2013 Aug 21.</citation>
    <PMID>23972932</PMID>
  </reference>
  <reference>
    <citation>Brown JM, O'Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg. 2009 Jan;137(1):82-90. doi: 10.1016/j.jtcvs.2008.08.015.</citation>
    <PMID>19154908</PMID>
  </reference>
  <reference>
    <citation>Maesen B, Nijs J, Maessen J, Allessie M, Schotten U. Post-operative atrial fibrillation: a maze of mechanisms. Europace. 2012 Feb;14(2):159-74. doi: 10.1093/europace/eur208. Epub 2011 Aug 6. Review.</citation>
    <PMID>21821851</PMID>
  </reference>
  <reference>
    <citation>Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021 Feb 1;42(5):507. Eur Heart J. 2021 Feb 1;42(5):546-547. Erratum in: Eur Heart J. 2021 Oct 21;42(40):4194.</citation>
    <PMID>32860505</PMID>
  </reference>
  <reference>
    <citation>Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, Whitlock RP. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD003611. doi: 10.1002/14651858.CD003611.pub3. Review.</citation>
    <PMID>23440790</PMID>
  </reference>
  <reference>
    <citation>AlTurki A, Marafi M, Proietti R, Cardinale D, Blackwell R, Dorian P, Bessissow A, Vieira L, Greiss I, Essebag V, Healey JS, Huynh T. Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery: A Systematic Review and Meta-Analysis. Circ Arrhythm Electrophysiol. 2020 Jan;13(1):e007437. doi: 10.1161/CIRCEP.119.007437. Epub 2020 Jan 16.</citation>
    <PMID>31944855</PMID>
  </reference>
  <reference>
    <citation>Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol. 2019 Jul;16(7):417-436. doi: 10.1038/s41569-019-0166-5. Review.</citation>
    <PMID>30792496</PMID>
  </reference>
  <reference>
    <citation>Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017 Oct 1;52(4):665-672. doi: 10.1093/ejcts/ezx039. Review.</citation>
    <PMID>28369234</PMID>
  </reference>
  <reference>
    <citation>Aguilar M, Dobrev D, Nattel S. Postoperative Atrial Fibrillation: Features, Mechanisms, and Clinical Management. Card Electrophysiol Clin. 2021 Mar;13(1):123-132. doi: 10.1016/j.ccep.2020.11.010. Review.</citation>
    <PMID>33516390</PMID>
  </reference>
  <reference>
    <citation>Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008 Jan 1;51(1):68-74. doi: 10.1016/j.jacc.2007.07.085.</citation>
    <PMID>18174039</PMID>
  </reference>
  <reference>
    <citation>Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM, Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol. 2012 Jan 3;59(1):60-70. doi: 10.1016/j.jacc.2011.08.062.</citation>
    <PMID>22192670</PMID>
  </reference>
  <reference>
    <citation>Scott L Jr, Li N, Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int J Cardiol. 2019 Jul 15;287:195-200. doi: 10.1016/j.ijcard.2018.10.020. Epub 2018 Oct 4. Review.</citation>
    <PMID>30316645</PMID>
  </reference>
  <reference>
    <citation>Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2017 May 1;38(17):1294-1302. doi: 10.1093/eurheartj/ehw045. Review.</citation>
    <PMID>26935271</PMID>
  </reference>
  <reference>
    <citation>Halonen J, Halonen P, Järvinen O, Taskinen P, Auvinen T, Tarkka M, Hippeläinen M, Juvonen T, Hartikainen J, Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007 Apr 11;297(14):1562-7.</citation>
    <PMID>17426275</PMID>
  </reference>
  <reference>
    <citation>Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med. 2016 May 5;374(18):1744-53. doi: 10.1056/NEJMoa1507750.</citation>
    <PMID>27144849</PMID>
  </reference>
  <reference>
    <citation>Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal. 2014 Mar 10;20(8):1268-85. doi: 10.1089/ars.2013.5542. Epub 2013 Oct 19. Review.</citation>
    <PMID>23924190</PMID>
  </reference>
  <reference>
    <citation>Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017 Jan 6;120(1):229-243. doi: 10.1161/CIRCRESAHA.116.308537. Review. Erratum in: Circ Res. 2018 Sep 28;123(8):e20.</citation>
    <PMID>28057795</PMID>
  </reference>
  <reference>
    <citation>Thiago L, Tsuji SR, Nyong J, Puga ME, Gois AF, Macedo CR, Valente O, Atallah ÁN. Statins for aortic valve stenosis. Cochrane Database Syst Rev. 2016 Sep 5;9:CD009571. doi: 10.1002/14651858.CD009571.pub2. Review.</citation>
    <PMID>27594276</PMID>
  </reference>
  <reference>
    <citation>Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43. Review.</citation>
    <PMID>15198965</PMID>
  </reference>
  <reference>
    <citation>Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003 Jan;63(1):12-23. Review.</citation>
    <PMID>12472764</PMID>
  </reference>
  <reference>
    <citation>Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2013 Jan;28(1):7-18. doi: 10.1097/HCO.0b013e32835b0956. Review.</citation>
    <PMID>23160338</PMID>
  </reference>
  <reference>
    <citation>Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2012 Nov;74(5):744-56. doi: 10.1111/j.1365-2125.2012.04258.x. Review.</citation>
    <PMID>22376147</PMID>
  </reference>
  <reference>
    <citation>Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg. 2008 Dec;136(6):1541-8. doi: 10.1016/j.jtcvs.2008.06.038. Epub 2008 Aug 15.</citation>
    <PMID>19114204</PMID>
  </reference>
  <reference>
    <citation>Almansob MA, Xu B, Zhou L, Hu XX, Chen W, Chang FJ, Ci HB, Yao JP, Xu YQ, Yao FJ, Liu DH, Zhang WB, Tang BY, Wang ZP, Ou JS. Simvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2304-13. doi: 10.1161/ATVBAHA.112.252098. Epub 2012 Jul 12.</citation>
    <PMID>22796581</PMID>
  </reference>
  <reference>
    <citation>Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH, Wahlers T. Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients. Eur J Cardiothorac Surg. 2014 Jan;45(1):17-26; discussion 26. doi: 10.1093/ejcts/ezt181. Epub 2013 Apr 5. Review.</citation>
    <PMID>23562936</PMID>
  </reference>
  <reference>
    <citation>Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev. 2015 Aug 13;(8):CD008493. doi: 10.1002/14651858.CD008493.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD008493.</citation>
    <PMID>26270008</PMID>
  </reference>
  <reference>
    <citation>Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006 Oct 3;114(14):1455-61. Epub 2006 Sep 25.</citation>
    <PMID>17000910</PMID>
  </reference>
  <reference>
    <citation>Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, Xie S, Chi L. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J. 2009 Dec;73(12):2244-9. Epub 2009 Oct 13.</citation>
    <PMID>19822977</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Ji Q, Mei Y, Wang X, Feng J, Cai J, Chi L. Role of preoperative atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting. Int Heart J. 2011;52(1):7-11.</citation>
    <PMID>21321461</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Zhang S, Jiang H, Sun A, Wang Y, Zou Y, Ge J, Chen H. Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. Arch Med Res. 2010 Aug;41(6):464-71. doi: 10.1016/j.arcmed.2010.08.009.</citation>
    <PMID>21044751</PMID>
  </reference>
  <reference>
    <citation>Vukovic PM, Maravic-Stojkovic VR, Peric MS, Jovic MDj, Cirkovic MV, Gradinac SDj, Djukanovic BP, Milojevic PS. Steroids and statins: an old and a new anti-inflammatory strategy compared. Perfusion. 2011 Jan;26(1):31-7. doi: 10.1177/0267659110385607. Epub 2010 Oct 4.</citation>
    <PMID>20921085</PMID>
  </reference>
  <reference>
    <citation>Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation. 2010 Sep 14;122(11 Suppl):S66-73. doi: 10.1161/CIRCULATIONAHA.109.927376.</citation>
    <PMID>20837928</PMID>
  </reference>
  <reference>
    <citation>Song YB, On YK, Kim JH, Shin DH, Kim JS, Sung J, Lee SH, Kim WS, Lee YT. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J. 2008 Aug;156(2):373.e9-16. doi: 10.1016/j.ahj.2008.04.020. Epub 2008 Jun 17.</citation>
    <PMID>18657672</PMID>
  </reference>
  <reference>
    <citation>Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, Carassiti M, Covino E. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med. 2006 Mar;34(3):660-7.</citation>
    <PMID>16505650</PMID>
  </reference>
  <reference>
    <citation>Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J. 2005 Mar;149(3):451-7.</citation>
    <PMID>15864233</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20-8.</citation>
    <PMID>15635109</PMID>
  </reference>
  <reference>
    <citation>Hashemzadeh K, Dehdilani M, Dehdilani M. Postoperative Atrial Fibrillation following Open Cardiac Surgery: Predisposing Factors and Complications. J Cardiovasc Thorac Res. 2013;5(3):101-7. doi: 10.5681/jcvtr.2013.022. Epub 2013 Oct 5.</citation>
    <PMID>24252985</PMID>
  </reference>
  <reference>
    <citation>Fragão-Marques M, Mancio J, Oliveira J, Falcão-Pires I, Leite-Moreira A. Gender Differences in Predictors and Long-Term Mortality of New-Onset Postoperative Atrial Fibrillation Following Isolated Aortic Valve Replacement Surgery. Ann Thorac Cardiovasc Surg. 2020 Dec 20;26(6):342-351. doi: 10.5761/atcs.oa.19-00314. Epub 2020 Apr 28.</citation>
    <PMID>32350163</PMID>
  </reference>
  <reference>
    <citation>Turagam MK, Downey FX, Kress DC, Sra J, Tajik AJ, Jahangir A. Pharmacological strategies for prevention of postoperative atrial fibrillation. Expert Rev Clin Pharmacol. 2015 Mar;8(2):233-50. doi: 10.1586/17512433.2015.1018182. Review.</citation>
    <PMID>25697411</PMID>
  </reference>
  <reference>
    <citation>Zebis LR, Christensen TD, Thomsen HF, Mikkelsen MM, Folkersen L, Sørensen HT, Hjortdal VE. Practical regimen for amiodarone use in preventing postoperative atrial fibrillation. Ann Thorac Surg. 2007 Apr;83(4):1326-31.</citation>
    <PMID>17383335</PMID>
  </reference>
  <reference>
    <citation>Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation. 2002 Jul 2;106(1):75-80.</citation>
    <PMID>12093773</PMID>
  </reference>
  <reference>
    <citation>Taira CA, Opezzo JA, Mayer MA, Höcht C. Cardiovascular drugs inducing QT prolongation: facts and evidence. Curr Drug Saf. 2010 Jan;5(1):65-72. Review.</citation>
    <PMID>20210721</PMID>
  </reference>
  <reference>
    <citation>Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816. doi: 10.1002/14651858.CD004816.pub5. Review.</citation>
    <PMID>23440795</PMID>
  </reference>
  <reference>
    <citation>Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015 Mar 12;(3):CD008226. doi: 10.1002/14651858.CD008226.pub3. Review.</citation>
    <PMID>25760954</PMID>
  </reference>
  <reference>
    <citation>Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006 Jan 1;97(1):61-7. Epub 2005 Nov 15.</citation>
    <PMID>16377285</PMID>
  </reference>
  <reference>
    <citation>Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.</citation>
    <PMID>21067804</PMID>
  </reference>
  <reference>
    <citation>Hansen MR, Hróbjartsson A, Pottegård A, Damkier P, Madsen KG, Pareek M, Olesen M, Hallas J. Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials. Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):286-296. doi: 10.1111/bcpt.13485. Epub 2020 Oct 8.</citation>
    <PMID>32896109</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Peter Riber</investigator_full_name>
    <investigator_title>MD, Associate Professor, Ph.D., DMSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

